Table 3. Results of Crossover (Mixed-Effect Model) Analysis, Stratified by Visual Acuity at Baseline (Post hoc Analysis). Bevacizumab.

and Ranibizumab columns represent the estimated effect of the drug for a 3-month period, adjusted for period and baseline value. The Difference column represents the estimated difference between the two drugs.

	Baseline visual acuity letter score	Bevacizumab [95% CI]	Ranibizumab [95% CI]	Difference [95% CI]	P-Value
Best-Corrected Visual Acuity, Change from Baseline (letters)	Any (all eyes)	5.3 [3.2, 7.4]	6.6 [4.5, 8.7]	1.3 [0.07, 2.5]	0.039
	≥ 69 letters	3.1 [0.2, 6.0]	3.6 [0.7, 6.5]	0.45 [−1.4, 2.3]	0.64
	< 69 letters	6.9 [4.3, 9.4]	8.7 [6.2, 11.3]	1.9 [0.3, 3.5]	0.022
OCT Central Subfield Mean Thickness, Change from Baseline (μm)	Any (all eyes)	−89 [−116, −62]	−137 [−164, −110]	−48 [−65, −31]	<0.001
	≥ 69 letters	−106 [−144, −68]	−145 [−183, −108]	−40 [−66, −14]	0.0032
	< 69 letters	−78 [−111, −45]	−132 [−165, −99]	−54 [−76, −31]	< 0.001